547 related articles for article (PubMed ID: 33287858)
1. Natural killer cell-based immunotherapy for acute myeloid leukemia.
Xu J; Niu T
J Hematol Oncol; 2020 Dec; 13(1):167. PubMed ID: 33287858
[TBL] [Abstract][Full Text] [Related]
2. Natural killer cells and acute myeloid leukemia: promises and challenges.
Rahmani S; Yazdanpanah N; Rezaei N
Cancer Immunol Immunother; 2022 Dec; 71(12):2849-2867. PubMed ID: 35639116
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer-Based "Off-the-Shelf" Acute Myeloid Leukemia Immunotherapies.
Kloess S; Oberschmidt O; Dahlke J; Vu XK; Neudoerfl C; Kloos A; Gardlowski T; Matthies N; Heuser M; Meyer J; Sauer M; Falk C; Koehl U; Schambach A; Morgan MA
Hum Gene Ther; 2019 Apr; 30(4):381-401. PubMed ID: 30734584
[TBL] [Abstract][Full Text] [Related]
4. Adoptive cell therapy for acute myeloid leukemia.
Ma H; Padmanabhan Iyer S; Parmar S; Gong Y
Leuk Lymphoma; 2019 Jun; 60(6):1370-1380. PubMed ID: 30628504
[TBL] [Abstract][Full Text] [Related]
5. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Hattori N; Nakamaki T
Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
[TBL] [Abstract][Full Text] [Related]
6. NK cell defects: implication in acute myeloid leukemia.
D'Silva SZ; Singh M; Pinto AS
Front Immunol; 2023; 14():1112059. PubMed ID: 37228595
[TBL] [Abstract][Full Text] [Related]
7. A Phase 1 Trial of CNDO-109-Activated Natural Killer Cells in Patients with High-Risk Acute Myeloid Leukemia.
Fehniger TA; Miller JS; Stuart RK; Cooley S; Salhotra A; Curtsinger J; Westervelt P; DiPersio JF; Hillman TM; Silver N; Szarek M; Gorelik L; Lowdell MW; Rowinsky E
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1581-1589. PubMed ID: 29597002
[TBL] [Abstract][Full Text] [Related]
8. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia.
Agrawal V; Gbolahan OB; Stahl M; Zeidan AM; Zaid MA; Farag SS; Konig H
Curr Cancer Drug Targets; 2020; 20(7):473-489. PubMed ID: 32357813
[TBL] [Abstract][Full Text] [Related]
9. Novel Immune Cell-Based Therapies to Eradicate High-Risk Acute Myeloid Leukemia.
Limongello R; Marra A; Mancusi A; Bonato S; Hoxha E; Ruggeri L; Hui S; Velardi A; Pierini A
Front Immunol; 2021; 12():695051. PubMed ID: 34413848
[TBL] [Abstract][Full Text] [Related]
10. Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells.
Carlsten M; Järås M
Front Immunol; 2019; 10():2357. PubMed ID: 31681270
[TBL] [Abstract][Full Text] [Related]
11. Emerging Immunotherapy for Acute Myeloid Leukemia.
Tabata R; Chi S; Yuda J; Minami Y
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669431
[TBL] [Abstract][Full Text] [Related]
12. Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia.
Dong H; Ham JD; Hu G; Xie G; Vergara J; Liang Y; Ali A; Tarannum M; Donner H; Baginska J; Abdulhamid Y; Dinh K; Soiffer RJ; Ritz J; Glimcher LH; Chen J; Romee R
Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122379119. PubMed ID: 35696582
[TBL] [Abstract][Full Text] [Related]
13. Circulating exosomes carrying an immunosuppressive cargo interfere with cellular immunotherapy in acute myeloid leukemia.
Hong CS; Sharma P; Yerneni SS; Simms P; Jackson EK; Whiteside TL; Boyiadzis M
Sci Rep; 2017 Oct; 7(1):14684. PubMed ID: 29089618
[TBL] [Abstract][Full Text] [Related]
14. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
15. An overview of the potential strategies for NK cell-based immunotherapy for acute myeloid leukemia.
Sinha C; Cunningham LC
Pediatr Blood Cancer; 2016 Dec; 63(12):2078-2085. PubMed ID: 27535002
[TBL] [Abstract][Full Text] [Related]
16. New approaches for the immunotherapy of acute myeloid leukemia.
Geiger TL; Rubnitz JE
Discov Med; 2015 Apr; 19(105):275-84. PubMed ID: 25977190
[TBL] [Abstract][Full Text] [Related]
17. Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Hu W; Wang G; Huang D; Sui M; Xu Y
Front Immunol; 2019; 10():1205. PubMed ID: 31214177
[TBL] [Abstract][Full Text] [Related]
18. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
19. The progress and current status of immunotherapy in acute myeloid leukemia.
Yang D; Zhang X; Zhang X; Xu Y
Ann Hematol; 2017 Dec; 96(12):1965-1982. PubMed ID: 29080982
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities.
Le Roy A; Prébet T; Castellano R; Goubard A; Riccardi F; Fauriat C; Granjeaud S; Benyamine A; Castanier C; Orlanducci F; Ben Amara A; Pont F; Fournié JJ; Collette Y; Mege JL; Vey N; Olive D
Front Immunol; 2018; 9():977. PubMed ID: 29780393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
